The Big Cancer52 Conversation

The Big Cancer52 Conversation

The Big Cancer52 Conversation on Wednesday 14th June brought together leaders from the charity, healthcare and pharmaceutical sectors, to share best practices, exchange ideas and explore collaborations, with the ultimate aim of improving outcomes for people with rare...
Dr Garan Jones – Research Grant Winner

Dr Garan Jones – Research Grant Winner

Winner of Neuroendocrine Cancer UK’s £30,000 grant for research Dr Garan Jones, the University of Exeter – “Our research project is titled “Determining the role of alternate splicing in the development of Small Intestine Neuroendocrine tumours...
Why do we have a Moth on our logo?

Why do we have a Moth on our logo?

In medicine, the term “zebra” is used in reference to a rare disease or condition. “If you hear hooves, you assume horse.” The rare disease community wants you to consider zebra. We agree with and advocate this message. However due to the rise in incidence of...
Radionuclides for Health UK

Radionuclides for Health UK

We advocate for the establishment of a stable UK supply of radionuclides for health and medical use. Our main focus is on the use of radionuclides in innovative cancer treatments such as molecular radiotherapy (i.e. the injection of radioactive substances for...
NHS Cancer Quality of Life Survey Launch

NHS Cancer Quality of Life Survey Launch

Monday 25th October saw the launch of the NHS Cancer Quality of Life Survey data dashboard. The survey is for people in England who have been diagnosed with cancer. From 2020, people who have had a breast, prostate or colorectal (bowel) cancer diagnosis are being...